Solitary Pulmonary Nodule — Written Clinical Reasoning

Model answer — Part A: the 9 mm solid nodule in a smoker

Frame the problem first. A 9 mm solid nodule in a 60-year-old heavy smoker sits above the 8 mm band where surveillance alone is no longer the default — this is a risk-stratification and tissue-question scenario, not a watch-and-wait one. My assessment has three aims: establish the temporal behaviour of the nodule, quantify malignancy probability, and choose between PET, biopsy and resection through the MDT [1] [2].

Assessment. History: smoking exposure and quit date, haemoptysis, weight loss, prior malignancy, occupational exposures, family history of lung cancer, and cardiorespiratory fitness that will shape any curative option. Examination: clubbing, supraclavicular nodes, chest signs. My first investigative move costs nothing — I hunt every prior image from every hospital, because a nodule stable for two years ends this workup and a growing one escalates it [1].

Characterise the nodule properly. I want a dedicated thin-section CT chest if the abdominal CT is technically limited, with formal description of margins (spiculation, lobulation), calcification or fat, and exact size — a 9 mm nodule with benign-pattern calcification is a different object from a 9 mm spiculated nodule [1].

Quantify the risk. I calculate rather than gesture: the Brock model combines age, sex, family history, emphysema with size, nodule type, upper-lobe location, spiculation and count. A 9 mm upper-lobe nodule in an older heavy smoker lands at least in the intermediate band — the band where PET-CT and biopsy live; BTS routes Brock probability of 10% or more to PET [2] [4].

Act on the band. Fleischner offers three options above 8 mm — 3-month CT, PET/CT or tissue — and in this patient PET/CT is the sensible referee: it characterises metabolic activity, detects occult nodal and distant disease, and directs the biopsy target. I quote its limits as I order it: sensitivity about 97% and specificity about 78%, falling below 8–10 mm, with false positives from granulomatous inflammation [1] [3].

Tissue if indicated, by the right route. An avid nodule or a high composite probability goes to the lung nodule MDT for biopsy-route selection — CT-guided for an accessible peripheral lesion (pneumothorax roughly one in five, chest drain about 5–7%, quoted to the patient), bronchoscopic if emphysema or a bronchus sign favours the airway, or straight to VATS if probability is high and he is fit [4] [5].

Close the loop. An honest conversation about what a 9 mm nodule means — most are not cancer, and this is how we will be certain; a written plan with dates; smoking-cessation support started now as the highest-yield intervention available [1].

Model answer — Part B: the 12 mm part-solid nodule with a 7 mm solid component

Name the entity correctly. This is a part-solid nodule, and part-solid nodules are managed by the solid component, not the overall diameter. A persistent part-solid nodule with a solid component of 6 mm or more is classified by Fleischner as highly suspicious — and part-solid morphology carries the highest malignancy frequency of any nodule type: 63% in the I-ELCAP analysis, versus 18% for pure nonsolid and 7% for solid nodules. This nodule needs tissue, not surveillance [1] [6].

Assessment. History and examination as for any suspected lung malignancy — smoking, symptoms, prior cancer, family history, fitness — plus the temporal question: the 4-month persistence check is done, so transient inflammation is no longer a reasonable explanation. I still retrieve any older imaging, because a documented solid component growing over time strengthens the case and a decade of stability would temper it [1].

Stage as I diagnose. PET/CT here has two jobs: characterise the solid component's avidity and survey nodes and distant sites to direct biopsy. I state its caveat — the ground-glass portion will be PET-cold, and only the solid component contributes signal [3].

Definitive pathway. With a 7 mm solid component and persistence, the MDT discussion is between CT-guided or bronchoscopic biopsy (if a benign result would change management) and — more commonly for a suspicious part-solid lesion in a fit patient — diagnostic-therapeutic VATS wedge with frozen section, proceeding to anatomical resection if invasive adenocarcinoma is confirmed. Part-solid lesions with small solid components are exactly the population in whom sublobar resection is oncologically defensible [4] [6].

Counselling. I explain in plain language: the scan shows a nodule with two parts — a hazy part and a solid core — and it is the solid core that concerns us; most people in her position turn out to have either an early, very curable cancer or something benign, and the next step answers which; if it is an early cancer, this is the stage at which surgery cures most people. I address the hip surgery sequencing honestly (the lung takes priority), set expectations about the MDT and timelines, invite her questions and her preferences, and document the conversation [1].

Common errors to avoid. Measuring the 12 mm overall diameter instead of the 7 mm solid component; ordering annual surveillance as if the solid component were under 6 mm; trusting a negative PET if the ground-glass component dominates the reading; and postponing the lung pathway until after the elective orthopaedic operation [1] [3].